Krystal Biotech, Inc. KRYS Proceeds from maturities of short-term investments
Proceeds from maturities of short-term investments at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s proceeds from maturities of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s proceeds from maturities of short-term investments?
- Krystal Biotech, Inc. (KRYS) reported proceeds from maturities of short-term investments of $103.6M in Q1 2026.
- How has Krystal Biotech, Inc.'s proceeds from maturities of short-term investments changed year-over-year?
- Krystal Biotech, Inc.'s proceeds from maturities of short-term investments increased by 16.7% year-over-year, from $88.81M to $103.6M.
- What is the long-term trend for Krystal Biotech, Inc.'s proceeds from maturities of short-term investments?
- Over 3 years (2021 to 2024), Krystal Biotech, Inc.'s proceeds from maturities of short-term investments has grown at a 110.5% compound annual growth rate (CAGR), from $32.03M to $298.54M.